Drug Trial Radar · NCT06807463
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Actual
Start
Mar 31, 2025
Primary completion
Oct 2, 2026
Study completion Sep 14, 2027
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Feb 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.
Conditions
- Celiac Disease
Interventions
TEV-53408Drug
Solution for subcutaneous (sc) injection
PlaceboDrug
Solution for subcutaneous (sc) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Villous Atrophy as Measured by Villous Height to Crypt Depth Ratio (Vh:Cd)Time frame: Baseline, Week 8
- Number of Participants With at Least One Treatment-Emergent Adverse EventTime frame: Up to Week 28
- Number of Participants With at Least One Treatment-Emergent Serious Adverse EventTime frame: Up to Week 28
- Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest (PDAESI)Time frame: Up to Week 28
- Number of Participants Who Discontinued From the Study Due to an Adverse EventTime frame: Up to Week 28
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Teva Investigational Site 12138
Murrieta, California
Teva Investigational Site 12131
Colorado Springs, Colorado
Teva Investigational Site 12134
Inverness, Florida
Teva Investigational Site 12126
Miami Lakes, Florida
Teva Investigational Site 12135
New Port Richey, Florida
Teva Investigational Site 12130
Atlanta, Georgia
Teva Investigational Site 12133
Marrero, Louisiana
Teva Investigational Site 12132
Clinton Township, Michigan
Teva Investigational Site 12121
Wyoming, Michigan
Teva Investigational Site 12129
Rochester, Minnesota
Teva Investigational Site 12128
New York, New York
Teva Investigational Site 12125
Greenville, North Carolina
Teva Investigational Site 12127
Winston-Salem, North Carolina
Teva Investigational Site 12137
Waco, Texas
Teva Investigational Site 12122
Ogden, Utah
Teva Investigational Site 12123
Lynchburg, Virginia
Teva Investigational Site 78139
Fitzroy, Australia
Teva Investigational Site 78140
Maroochydore, Australia
Teva Investigational Site 78137
Midland, Australia
Teva Investigational Site 40063
Helsinki, Finland
Teva Investigational Site 40062
Tampere, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.